HIF1A and head and neck squamous cell carcinoma: For example, an epidermal growth factor receptor (EGFR) inhibitor, cetuximab, which is approved by the FDA, suppresses the expression of HIF-1α and sensitizes head and neck squamous cell carcinoma (HNSCC) cells to radiotherapy [49].